 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | allogeneic Myeloma GM-CSF Vaccine / Sidney Kimmel Comprehensive Cancer Center
Trial completion date: Allogeneic Myeloma GM-CSF Vaccine With Lenalidomide in Multiple Myeloma Patients in Complete or Near Complete Remission (clinicaltrials.gov) - Oct 29, 2024
P2, N=54, Active, not recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Trial completion date: Sep 2024 --> Dec 2024
- || allogeneic Myeloma GM-CSF Vaccine / Sidney Kimmel Comprehensive Cancer Center
Trial completion date, Trial primary completion date: Allogeneic Myeloma GM-CSF Vaccine With Lenalidomide in Multiple Myeloma Patients in Complete or Near Complete Remission (clinicaltrials.gov) - Feb 24, 2023
P2, N=54, Active, not recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Trial completion date: Sep 2024 --> Dec 2024 Trial completion date: Dec 2023 --> Sep 2024 | Trial primary completion date: Jan 2023 --> Mar 2024
- || allogeneic Myeloma GM-CSF Vaccine / Sidney Kimmel Comprehensive Cancer Center
Enrollment closed: Allogeneic Myeloma GM-CSF Vaccine With Lenalidomide in Multiple Myeloma Patients in Complete or Near Complete Remission (clinicaltrials.gov) - Sep 14, 2022
P2, N=54, Active, not recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Trial completion date: Dec 2023 --> Sep 2024 | Trial primary completion date: Jan 2023 --> Mar 2024 Recruiting --> Active, not recruiting
- || lenalidomide / Generic mfg.
Clinical, Journal: An allogeneic multiple myeloma GM-CSF-secreting vaccine with lenalidomide induces long-term immunity and durable clinical responses in patients in near complete remission. (Pubmed Central) - Apr 8, 2022
MM-GVAX, along with lenalidomide, effectively primed durable immunity and resulted long-term disease control, as suggested by the reappearance of a detectable, fluctuating M-spike without meeting the criteria for clinical relapse. For patients in a nCR, MM-GVAX administration was safe and resulted in prolonged clinical responses.
- || allogeneic Myeloma GM-CSF Vaccine / Sidney Kimmel Comprehensive Cancer Center
Trial primary completion date: Allogeneic Myeloma GM-CSF Vaccine With Lenalidomide in Multiple Myeloma Patients in Complete or Near Complete Remission (clinicaltrials.gov) - Jan 10, 2022
P2, N=54, Recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
For patients in a nCR, MM-GVAX administration was safe and resulted in prolonged clinical responses. Trial primary completion date: Oct 2022 --> Jan 2023
- || allogeneic Myeloma GM-CSF Vaccine / Sidney Kimmel Comprehensive Cancer Center
Trial primary completion date: Allogeneic Myeloma GM-CSF Vaccine With Lenalidomide in Multiple Myeloma Patients in Complete or Near Complete Remission (clinicaltrials.gov) - Dec 19, 2020
P2, N=54, Recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Trial primary completion date: Oct 2022 --> Jan 2023 Trial primary completion date: Oct 2021 --> Oct 2022
- ||| allogeneic Myeloma GM-CSF Vaccine / Sidney Kimmel Comprehensive Cancer Center
Enrollment open: Allogeneic Myeloma GM-CSF Vaccine With Lenalidomide in Multiple Myeloma Patients in Complete or Near Complete Remission (clinicaltrials.gov) - Jul 5, 2019
P2, N=54, Recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Trial primary completion date: Oct 2021 --> Oct 2022 Not yet recruiting --> Recruiting
- || allogeneic Myeloma GM-CSF Vaccine / Sidney Kimmel Comprehensive Cancer Center
Trial primary completion date: Allogeneic Myeloma GM-CSF Vaccine With Lenalidomide in Multiple Myeloma Patients in Complete or Near Complete Remission (clinicaltrials.gov) - May 22, 2019
P2, N=54, Not yet recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Not yet recruiting --> Recruiting Trial primary completion date: Oct 2020 --> Oct 2021
- | allogeneic Myeloma GM-CSF Vaccine / Sidney Kimmel Comprehensive Cancer Center
Enrollment open: Allogeneic Myeloma GM-CSF Vaccine With Lenalidomide in Multiple Myeloma Patients in Complete or Near Complete Remission (clinicaltrials.gov) - Sep 6, 2018
P2, N=56, Recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Trial primary completion date: Oct 2020 --> Oct 2021 Not yet recruiting --> Recruiting
- ||| allogeneic Myeloma GM-CSF Vaccine / Sidney Kimmel Comprehensive Cancer Center
Trial initiation date: Allogeneic Myeloma GM-CSF Vaccine With Lenalidomide in Multiple Myeloma Patients in Complete or Near Complete Remission (clinicaltrials.gov) - Apr 18, 2018
P2, N=56, Not yet recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Not yet recruiting --> Recruiting Initiation date: Feb 2018 --> Jun 2018
- ||||| allogeneic Myeloma GM-CSF Vaccine / Sidney Kimmel Comprehensive Cancer Center
New P2 trial: Allogeneic Myeloma GM-CSF Vaccine With Lenalidomide in Multiple Myeloma Patients in Complete or Near Complete Remission (clinicaltrials.gov) - Dec 18, 2017
P2, N=56, Not yet recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
- | allogeneic Myeloma GM-CSF Vaccine / Sidney Kimmel Comprehensive Cancer Center, BMS, Novartis
Trial completion, Enrollment change, Trial primary completion date: Allogeneic GM-CSF Vaccine and Lenalidomide in Treating Myeloma Patients With Near Complete Remission (clinicaltrials.gov) - Oct 13, 2016
P2, N=18, Completed, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Initiation date: Feb 2018 --> Jun 2018 Active, not recruiting --> Completed | N=15 --> 18 | Trial primary completion date: Jun 2015 --> Oct 2016
- | allogeneic Myeloma GM-CSF Vaccine / Sidney Kimmel Comprehensive Cancer Center, BMS, Novartis
Enrollment closed: Allogeneic GM-CSF Vaccine and Lenalidomide in Treating Myeloma Patients With Near Complete Remission (clinicaltrials.gov) - Apr 1, 2015
P2, N=15, Active, not recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Active, not recruiting --> Completed | N=15 --> 18 | Trial primary completion date: Jun 2015 --> Oct 2016 Recruiting --> Active, not recruiting
- | allogeneic Myeloma GM-CSF Vaccine / Sidney Kimmel Comprehensive Cancer Center, BMS, Novartis
Trial initiation date: Allogeneic GM-CSF Vaccine and Lenalidomide in Treating Myeloma Patients With Near Complete Remission (clinicaltrials.gov) - Mar 6, 2012
P2, N=15, Recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Recruiting --> Active, not recruiting Initiation date: Jun 2011 --> Jan 2012
- | allogeneic Myeloma GM-CSF Vaccine / Sidney Kimmel Comprehensive Cancer Center, BMS, Novartis
Enrollment open: Allogeneic GM-CSF Vaccine and Lenalidomide in Treating Myeloma Patients With Near Complete Remission (clinicaltrials.gov) - Mar 6, 2012
P2, N=15, Recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Initiation date: Jun 2011 --> Jan 2012 Not yet recruiting --> Recruiting